Fri, 1 Nov 2024

 

NDLEA warns public of new drug, Fentanyl
 
By: News Editor
Tue, 8 Nov 2022   ||   Nigeria, Abuja
 

The National Drug Law Enforcement Agency (NDLEA) has said it has detected plans of some unscrupulous elements to introduce an illicit drug, Fentanyl, into the Nigerian market.
The agency disclosed this in a statement signed by its Director of Media and Advocacy, Femi Babafemi, on Tuesday.
NDLEA said Fentanyl is 100 times stronger than Tramadol, stressing that the illicitly manufactured drug is capable of causing mass casualty among the youth population being targeted by the cartels.
The agency said every step must be taken to ensure that the drug, which is responsible for over 70 percent of overdose deaths as well as a major contributor to fatal and nonfatal overdoses in the US, is not allowed to circulate in Nigeria because of its lethality and the current drug abuse prevalence of 14.4% in the Country.
The agency said; “We are not unaware of desperate efforts by some drug cartels to introduce to the Nigerian market, Fentanyl, which according to the CDC, is 80 times as potent as morphine and 100 times more potent than heroin.''
“This, they plan to do either in liquid or powder form and/or with misleading labels to target our youth population.''
“This they may also mix with other prescription drugs. The illegally manufactured fentanyl in its liquid form can come in nasal sprays, eye drops, or small candies.''
“As a result, parents and other stakeholders are advised to be vigilant, alert and warn their young ones against attempting experimenting with this illicit substance. Symptoms for fentanyl exposure and/or overdose include pinpoint pupils, falling asleep or losing consciousness, slow and shallow breathing, choking or gurgling sounds, limp body, and pale, blue, or cold skin.”
‘’The agency wishes to assure the public that all necessary assets have been deployed to monitor the cartels involved with a view to frustrating their criminal plot and make them face the wrath of the law.’’

 

 

Tag(s):
 
 
Back to News